YDJC

Across TCGA pan-cancer cohorts, YDJC Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated YDJC data layer compared with 20 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher YDJC Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated YDJC expression acts as an unfavorable survival marker.

LUSC and UCEC are the cancer types where YDJC Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	II,III,IV	0.139	0.761	<.001	24	view →
UCEC	OS	Median	II,III,IV	0.231	0.768	.010	24	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

YDJC–LUSC (DFS)

Open the LUSC breakdown →